Background The benign and malignant patterns of acral melanocytic naevi (AMN) and acral melanomas (AM) have
Introduction
Acral melanocytic naevi (AMN) and acral melanomas (AM) can be difficult to interpret dermoscopically and are associated with a worse prognosis than non-acral cutaneous melanomas (CM). 1 The benign and malignant patterns of AMN and AM have been defined in a series of retrospective studies. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Several clinically useful patterns have been described, including benign, malignant and indeterminate patterns. Benign patterns include parallel furrow, lattice-like and regular fibrillar. 12 The three malignant patterns are parallel ridge, multicomponent and diffuse irregular pigmentation. 2, 4, 10, 11 Indeterminate patterns include reticular, globular, homogeneous and non-typical patterns. 12 Recently, an evidence-based, three-step algorithm was developed using clinical and dermoscopic features. [12] [13] [14] In this algorithm, all parallel ridge patterns require a biopsy. Parallel furrow, lattice-like and regular fibular patterns do not require a biopsy. For any lesion not conforming to one of these four patterns, a biopsy is performed if the diameter of the lesion is >7 mm. Although easy to use, the utility of the three-step algorithm has not been confirmed in a non-Japanese population. For indeterminate or intermediate risk acral melanocytic lesions, close clinical follow-up may be warranted instead of a biopsy. Many factors determine whether clinical follow-up is appropriate, including the assessed risk of the lesion, the location of the lesion, patient preference and patient reliability. In non-acral CM, the most important clinical features are a new or changing lesion, dermoscopic impression and patient concerns. 15, 16 Interestingly, there are little data on these clinical factors and decision-making in acral locations. Our study aimed to review the current management strategy of acral melanocytic lesions and to investigate the utility of the three-step algorithm in a predominately Caucasian cohort. Due to the poor outcomes in AM, success was defined as 100% sensitivity to advocate for a biopsy of AM.
Methods
The institutional review board at Mayo Clinic approved this study. A retrospective search of all pathology records between 2006 and 2016 at Mayo Clinic Arizona was performed. Search terms included the following: acral naevus, acral melanocytic naevus, naevus, naevi, melanoma or acral melanoma with foot, feet, plantar, toe, heel, sole, digit, hand, hands, finger, thumb, palm or palmar. This search identified 293 cases. All pathology reports and clinical and dermoscopic photographs were reviewed to confirm the diagnosis and the location. All cases that did not have dermoscopic photographs or lesions on non-volar surfaces were excluded. A total of 27 cases met all criteria for inclusion.
A second search of our image database of biopsied and nonbiopsied lesions, collected from mid-2010 through 2016, was performed using anatomically limiting search terms: foot, feet, plantar, toe, heel, sole, digit, hand, hands, finger, thumb, palm or palmar. A total of 5859 images were identified, and the clinical and dermoscopic images and the medical records were reviewed. All naevi and melanomas with clinical and dermoscopic images were recorded, and duplicates from the pathology search were removed. All cases on non-volar surfaces were excluded. This search identified an additional 21 cases that were biopsied and 73 cases that were followed clinically.
Demographic data were collected from chart reviews, including age at diagnosis, gender, history of non-melanoma skin cancer and history of melanoma. During the chart reviews, data on who initiated the request for a biopsy (defined as the physicianinitiated when the physician documented clinical concern for the lesion being biopsied, patient-initiated when the patient presented with a lesion they were concerned of, patient directed without physician recommendation when patient concern was documented as the reason for biopsy and the physician's examination documented the benign clinical appearance) and the reason for biopsy (new lesion, changing lesion, symptomatic, physician-deemed concerning dermoscopic pattern and patient concern) was collected. For individuals followed clinically, the recommended follow-up times and actual follow-up times were recorded. All lesions with known diameter and pathological diagnosis were used for the three-step algorithm.
Two experienced dermatologists (DLS and ARM), blinded to the outcomes, reviewed all 121 dermoscopic images using the definitions in Table 1 . Each dermoscopic image was independently assigned a global dermoscopic pattern that best represented the lesion by each reviewer (Fig. 1 ). All global patterns were then re-reviewed, and a consensus was made on any discrepant cases.
Statistical analysis was performed using frequencies and proportions for categorical variables, and mean, standard deviation, median and range for continuous variables. A comparison between groups was conducted using the Wilcoxon rank sum test for continuous variables, and the Pearson chi-squared test for categorical variables. The significance level was at 0.05. The analysis was performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
A total 121 acral melanocytic lesions were identified; 73 were clinically followed, and 48 were biopsied. A total of 45 biopsied lesions were located on the soles, and three were located on the palms. For the clinically followed lesions, 64 were located on the soles and nine on the palms.
There were five patients with AM (0 male and five female), 43 with AMN (18 male and 25 female) and 73 with clinically followed lesions (27 male and 46 female). The ethnicities were Caucasian (70.2%), African American (17.4%), Asian (5.0%), Hispanic (3.3%) Native American (0.8%), Pacific Islander (0.8%) and unknown (2.5%). A total of 4.1% of patients had a history of melanoma, 11.6% had a history of non-melanoma skin cancer, and 0.8% had a history of both. There were no significant differences in ethnicity or gender between biopsied and clinically followed lesions or the diagnosis of AMN and AM. Individuals with a history of skin cancer were more likely to be biopsied (P = 0.02). Patients who were followed clinically were significantly younger than those who underwent biopsy [49.1 years (SD = 15.6) vs. 55.6 years (SD = 16.6), P = 0.04].
The dermoscopic patterns that were more likely to be biopsied than followed clinically were the regular fibrillar and parallel ridge patterns. Four fibrillar pattern lesions were followed and 10 biopsied (P = 0.01). No parallel ridge pattern lesions were followed, and five were biopsied (P = 0.01). In contrast, the parallel furrow pattern naevi were followed 21 times and biopsied five times (P = 0.02). The remaining benign and malignant patterns had no significant difference between the rate of biopsy and clinical follow-up (Table 2) .
Of biopsied lesions, the parallel ridge pattern (P = 0.01) and multicomponent (P = 0.03) were more likely to be malignant patterns. All other patterns were not significantly associated with benign or malignant pathology. The malignant lesions were non-significantly larger (12.0 mm, SD = 15.7, P = 0.25) than the benign lesions (5.2 mm, SD = 2.8; Table 2 *Likely to be benign, recommended to not be biopsied regardless of size. 13 †Likely to be benign; however, they should be biopsied if larger than 7 mm.
13 ‡More likely to be malignant. When physician-deemed concerning dermoscopic patterns were the reason for biopsy, upon review of the dermoscopy images, 39.2% of cases were either parallel furrow, lattice-like or regular fibrillar. 42.9% of the cases were indeterminate patterns including homogeneous, reticular, globular or non-typical patterns. 17.9% of the cases were parallel ridge or multicomponent.
For non-biopsied acral lesions, physician recommendations were as follows: 64.4% for no close follow-up (defined as no follow-up besides an annual skin examination), 32.9% for close follow-up within 3-6 month, and 2.7% did not have specific recommendations. The mean recommended follow-up interval was 4.4 months. When close follow-up was recommended, 16.7% of the patients followed up within the recommended time interval, 33.3% of patients followed up outside of the recommended time interval (mean = 19.4 months), and 50.0% did not follow-up.
All biopsied volar acral lesions with a known lesion diameter, 40 AMN and five AM, were reviewed using the three-step algorithm (Fig. 2) . The three-step algorithm correctly identified four of five (80%) AMs for biopsy. A multicomponent pattern (atypical network, atypical lattice and atypical globules), 0.5 mm Breslow thickness, 6 mm in diameter lesion, was missed (Fig. 3) . The sensitivity of the three-step algorithm was 80.0%, specificity 87.8%, PPV of 44.4% and the NPV 97.2% (Table S1 ).
Discussion
Acral melanocytic lesions remain a diagnostic challenge. Our study examined the clinical and dermoscopic features of biopsied and followed AMN and AM to review our current management strategy. We found one major educational gap and two major practice gaps, including the recognition of low-risk benign lesions, poor patient compliance with follow-up and the potential insensitivity of the three-step algorithm to small multicomponent acral melanocytic lesions. Physicians often do not recognize regular fibrillar as a benign pattern. Of nearly 40% of the lesions biopsied due to physician-deemed concerning dermoscopic pattern, the patterns were low risk and did not require biopsy, regardless of size. Overall, patients have poor follow-up to re-examine acral lesions within a 3-6-month time frame. Only 16.7% of patient followed up on time and 50% did not follow up. Lastly, we confirmed the utility of the three-step algorithm in a predominately Caucasian population, albeit missing on 6 mm AM with a multicomponent pattern. The addition of the multicomponent pattern as high risk, requiring a biopsy, to the three-step algorithm will ameliorate this potential pitfall.
Parallel furrow, lattice-like and regular fibrillar patterns are considered low risk in the three-step algorithm, and, within our study, none of these patterns were malignant. We found that parallel furrow is less likely to be biopsied (P = 0.02), while regular fibrillar and parallel ridge were more likely to be biopsied (P = 0.01, P = 0.01). This suggests that parallel furrow is an easily recognized benign pattern, and parallel ridge is an easily recognized malignant pattern. Our results demonstrate that there is an incomplete understanding and interpretation of the regular fibrillar pattern, which is actually a secondary pattern that results from shear displacement of the stratum corneum. 3 Better education is needed on how to examine fibrillar pattern acral melanocytic lesions. The best technique is to utilize a tangential, oblique dermoscopic angle when visualizing acral melanocytic lesions. 3 This determines the origin of the pigment as furrow or ridge, noting that the latter is a malignant pattern. The clinical factors that led to biopsy or clinical follow-up were examined. Individuals with a history of skin cancer were more likely to be biopsied (P = 0.02), and younger individuals were more likely to be followed clinically (49.1 vs. 55.6 years, P = 0.04). Additionally, all individuals with AM were female. The current study is underpowered to establish age, sex and history of skin cancer as additional diagnostic classifiers for the analysis of acral melanocytic lesions. Future studies should be undertaken to determine which clinical classifiers are independent predictors of malignancy. The reasons for biopsy included physician-deemed concerning dermoscopic features in 58.1% and 60% of AMN and AM, respectively, a changing lesion in 20.9% and 0% of AMN and AM, respectively, and a new lesion in 16.3% for AMN and 20% for AM, respectively. Previous studies have investigated the reasons for biopsies of non-acral cutaneous naevi and CM, including dermoscopic impressions, new lesions and changing lesions. 15, 16 In those studies, the strongest predictor of biopsy was 'physician concern', including atypical gross or dermoscopic appearances.
Our study found that physician-deemed concerning dermoscopic patterns were the strongest predictors of biopsy of AMN and AM. Reinterpretations of the physician-deemed concerning patterns by two trained dermoscopists found that 39.2% were benign parallel furrow, lattice-like or regular fibrillar patterns. This suggests the need for additional dermoscopy training for both residents and physicians. A recent survey of 139 dermatology chief residents found that 94% use dermoscopy; however, only 48% trained with a pigmented lesions specialist. 17 In our series, better training in acral-pigmented lesions may have decreased the biopsy rate of AMN by 23.3% (Table S1 ). In our review of clinically followed acral melanocytic lesions, only 16.7% of the patients followed up within the recommended time interval, 33% followed up outside of the time interval and 50% never returned. This finding was unexpected and may be practice changing. Rates of follow-up for non-acral melanocytic lesions, in Europe and Australia, show an inverse relationship between compliance and follow-up interval with compliance rates of 84%, 46-63% and 30% for 3-month, 6-month and 12-month follow-up, respectively. [18] [19] [20] Due to poor clinical followup overall and the inverse relationship between follow-up interval and compliance, we caution any clinical follow-up of nonbenign pattern acral melanocytic lesions. For reliable patients, we recommend clinical follow-up intervals of <3 months with indeterminate dermoscopic patterns and biopsy for high-risk acral dermoscopic patterns. The three-step algorithm correctly identified four of five volar AM (Fig. 2) . However, a 6 mm, multicomponent (atypical network, atypical lattice and atypical globules), invasive AM was missed. This lesion was located at the junction of the heel and the arch on the volar foot. The combination of a 'low' and 'high' mechanical stress area may account for the atypical appearance. 21 We advocate for the inclusion of the multicomponent pattern as a high-risk dermoscopic pattern that should be biopsied regardless of lesion size. Multiple studies have found a positive correlation between size and malignancy in melanocytic lesions with non-benign volar dermoscopic patterns. 10, 12, 22 The 7-mm cut-off should be used when deciding to biopsy indeterminate lesions. Previous reports have demonstrated that parallel ridge, multicomponent and irregular diffuse pigmentation are all malignant patterns on the volar surface. 2,4,11 Based on our findings, the multicomponent and the parallel ridge patterns should be biopsied regardless of lesion diameter. Our study is limited in its retrospective design. Dermoscopic and clinical photographs were only obtained on clinically concerning or biopsied lesions, which led to selection bias. Our sample size was small, limiting our study's analysis of the three-step algorithm. However, despite the small number of volar AM, the three-step algorithm missed one of five AM. Future studies are warranted to examine the three-step algorithm with the inclusion of the multicomponent pattern in a larger sample population as well as to examine age, sex and history of skin cancer as additional risk classifiers.
Conclusions
Acral melanocytic lesions can be difficult to interpret. The regular fibrillar pattern had the highest biopsy rate of benign lesions. Recognizing that parallel furrow, lattice-like and regular fibrillar are low-risk dermoscopic patterns could reduce the rate of biopsy of AMN by 23.3%. Patients have poor compliance with clinical follow-up of acral melanocytic lesions. Therefore, caution should be used when following any non-benign pattern acral melanocytic lesion. Clinical follow-up of <3 months for indeterminate dermoscopic patterns and biopsy of all high-risk dermoscopic patterns may be appropriate. The three-step algorithm is useful to decide when to biopsy acral melanocytic lesions. To improve the sensitivity, the multicomponent pattern should be added as a size-independent high-risk lesion to the three-step algorithm.
